» Articles » PMID: 16529910

Predictors of Antipsychotic Medication Adherence in Patients Recovering from a First Psychotic Episode

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 2006 Mar 15
PMID 16529910
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Many patients recovering from a first psychotic episode will discontinue medication against medical advice, even before a 1-year treatment course is completed. Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects.

Method: In this 2-year prospective study of 254 patients recovering from a first episode of schizophrenia, schizophreniform, or schizoaffective disorder we examined the relationship between antipsychotic medication non-adherence and patient beliefs about: need for treatment, antipsychotic medication benefits, and negative aspects of antipsychotic medication treatment. We also examined the relationship between medication non-adherence and treatment with either haloperidol or olanzapine, and objective measures of symptom response and side effects.

Results: The likelihood of becoming medication non-adherent for 1 week or longer was greater in subjects whose belief in need for treatment was less (HR=1.75, 95% CI 1.16, 2.65, p=0.0077) or who believed medications were of low benefit (HR=2.88, 95 CI 1.79-4.65, p<0.0001). Subjects randomized to haloperidol were more likely to become medication non-adherent for >or=1 week than subjects randomized to olanzapine (HR-1.51, 95% CI 1.01, 2.27, p=0.045).

Conclusion: Beliefs about need for treatment and the benefits of antipsychotic medication may be intervention targets to improve likelihood of long-term medication adherence in patients recovering from a first episode of schizophrenia, schizoaffective, or schizophreniform disorder.

Citing Articles

Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis.

Sherzad Qadir Z, Ball P, Morrissey H Pharmacy (Basel). 2023; 11(6).

PMID: 37987385 PMC: 10661248. DOI: 10.3390/pharmacy11060175.


Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.

Olivares J, Fagiolini A Front Psychiatry. 2022; 13:877867.

PMID: 35573364 PMC: 9096029. DOI: 10.3389/fpsyt.2022.877867.


Specialized inpatient treatment for young people with early psychosis: acute-treatment and 12-month results.

Siebert S, Leopold K, Baumgardt J, von Hardenberg L, Burkhardt E, Bechdolf A Eur Arch Psychiatry Clin Neurosci. 2022; 272(7):1-14.

PMID: 35141809 PMC: 9508217. DOI: 10.1007/s00406-022-01379-8.


Does Spiritual Well-Being Affect Medication Adherence in Individuals Diagnosed with Mental Illness in Turkey?.

Gultekin A, Budak F J Relig Health. 2021; 61(1):64-78.

PMID: 34213701 DOI: 10.1007/s10943-021-01322-6.


Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study.

Olivares J, Gonzalez-Pinto A, Paramo M Eur Psychiatry. 2021; 64(1):e40.

PMID: 33840396 PMC: 8260564. DOI: 10.1192/j.eurpsy.2021.23.